These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
49. Familial evaluation in catecholaminergic polymorphic ventricular tachycardia: disease penetrance and expression in cardiac ryanodine receptor mutation-carrying relatives. van der Werf C; Nederend I; Hofman N; van Geloven N; Ebink C; Frohn-Mulder IM; Alings AM; Bosker HA; Bracke FA; van den Heuvel F; Waalewijn RA; Bikker H; van Tintelen JP; Bhuiyan ZA; van den Berg MP; Wilde AA Circ Arrhythm Electrophysiol; 2012 Aug; 5(4):748-56. PubMed ID: 22787013 [TBL] [Abstract][Full Text] [Related]
50. Guidelines for the diagnosis and management of Catecholaminergic Polymorphic Ventricular Tachycardia. Pflaumer A; Davis AM Heart Lung Circ; 2012 Feb; 21(2):96-100. PubMed ID: 22119737 [TBL] [Abstract][Full Text] [Related]
51. Prevention of ventricular arrhythmia and calcium dysregulation in a catecholaminergic polymorphic ventricular tachycardia mouse model carrying calsequestrin-2 mutation. Alcalai R; Wakimoto H; Arad M; Planer D; Konno T; Wang L; Seidman JG; Seidman CE; Berul CI J Cardiovasc Electrophysiol; 2011 Mar; 22(3):316-24. PubMed ID: 20807279 [TBL] [Abstract][Full Text] [Related]
52. Clinical and genetic investigation of catecholaminergic polymorphic ventricular tachycardia in a consanguineous Tunisian family. Nouira S; Chabrak S; Ouragini H Acta Cardiol; 2020 Nov; 75(7):677-680. PubMed ID: 31453761 [No Abstract] [Full Text] [Related]
53. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. van der Werf C; Kannankeril PJ; Sacher F; Krahn AD; Viskin S; Leenhardt A; Shimizu W; Sumitomo N; Fish FA; Bhuiyan ZA; Willems AR; van der Veen MJ; Watanabe H; Laborderie J; Haïssaguerre M; Knollmann BC; Wilde AA J Am Coll Cardiol; 2011 May; 57(22):2244-54. PubMed ID: 21616285 [TBL] [Abstract][Full Text] [Related]
54. The Antiarrhythmic Mechanisms of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia. Li Y; Peng X; Lin R; Wang X; Liu X; Bai R; Ma C; Tang R; Ruan Y; Liu N Front Physiol; 2022; 13():850117. PubMed ID: 35356081 [TBL] [Abstract][Full Text] [Related]
55. Bidirectional ventricular tachycardia and fibrillation elicited in a knock-in mouse model carrier of a mutation in the cardiac ryanodine receptor. Cerrone M; Colombi B; Santoro M; di Barletta MR; Scelsi M; Villani L; Napolitano C; Priori SG Circ Res; 2005 May; 96(10):e77-82. PubMed ID: 15890976 [TBL] [Abstract][Full Text] [Related]
56. Left cardiac sympathetic denervation for the management of life-threatening ventricular tachyarrhythmias in young patients with catecholaminergic polymorphic ventricular tachycardia and long QT syndrome. Schneider HE; Steinmetz M; Krause U; Kriebel T; Ruschewski W; Paul T Clin Res Cardiol; 2013 Jan; 102(1):33-42. PubMed ID: 22821214 [TBL] [Abstract][Full Text] [Related]
57. The clinical and genetic spectrum of catecholaminergic polymorphic ventricular tachycardia: findings from an international multicentre registry. Roston TM; Yuchi Z; Kannankeril PJ; Hathaway J; Vinocur JM; Etheridge SP; Potts JE; Maginot KR; Salerno JC; Cohen MI; Hamilton RM; Pflaumer A; Mohammed S; Kimlicka L; Kanter RJ; LaPage MJ; Collins KK; Gebauer RA; Temple JD; Batra AS; Erickson C; Miszczak-Knecht M; Kubuš P; Bar-Cohen Y; Kantoch M; Thomas VC; Hessling G; Anderson C; Young ML; Choi SHJ; Cabrera Ortega M; Lau YR; Johnsrude CL; Fournier A; Van Petegem F; Sanatani S Europace; 2018 Mar; 20(3):541-547. PubMed ID: 28158428 [TBL] [Abstract][Full Text] [Related]
58. Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia. Rosso R; Kalman JM; Rogowski O; Diamant S; Birger A; Biner S; Belhassen B; Viskin S Heart Rhythm; 2007 Sep; 4(9):1149-54. PubMed ID: 17765612 [TBL] [Abstract][Full Text] [Related]
59. The Hyperpolarization-Activated Cyclic-Nucleotide-Gated Channel Blocker Ivabradine Does Not Prevent Arrhythmias in Catecholaminergic Polymorphic Ventricular Tachycardia. Bueno-Levy H; Weisbrod D; Yadin D; Haron-Khun S; Peretz A; Hochhauser E; Arad M; Attali B Front Pharmacol; 2019; 10():1566. PubMed ID: 32009964 [TBL] [Abstract][Full Text] [Related]
60. Importance of ventricular tachycardia storms not terminated by implantable cardioverter defibrillators shocks in patients with CASQ2 associated catecholaminergic polymorphic ventricular tachycardia. Marai I; Khoury A; Suleiman M; Gepstein L; Blich M; Lorber A; Boulos M Am J Cardiol; 2012 Jul; 110(1):72-6. PubMed ID: 22481011 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]